/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Emergent BioSolutions Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$11.47 0.0691(6.91%) EBS at 04 Dec 2025 04:30 PM Drug Manufacturers - Specialty & Generic
Lowest Today 11
Highest Today 11.69
Today’s Open 11
Prev. Close 10.85
52 Week High 13.41
52 Week Low 4.02
Day’s Range: Low 11 High 11.69
52-Week Range: Low 4.02 High 13.41
1 day return -
1 Week return +3.7
1 month return +14.95
3 month return +52.19
6 month return +82.75
1 year return +22.8
3 year return -1.48
5 year return -85.98
10 year return -

Institutional Holdings

BlackRock Inc 8.17

Oak Hill Advisors LP 6.77

Vanguard Group Inc 6.72

American Century Companies Inc 4.30

Avantis US Small Cap Value ETF 3.61

Dimensional Fund Advisors, Inc. 3.47

State Street Corp 3.26

Vanguard Total Stock Mkt Idx Inv 2.95

iShares Russell 2000 ETF 2.45

Geode Capital Management, LLC 2.40

Charles Schwab Investment Management Inc 2.07

Palisade Capital Management LLc 2.06

Marshall Wace Asset Management Ltd 1.91

Connor Clark & Lunn Inv Mgmt Ltd 1.85

SPDR® S&P Biotech ETF 1.78

LSV Asset Management 1.53

Prescott Group Capital Management LLC 1.45

Millennium Management LLC 1.42

Morgan Stanley - Brokerage Accounts 1.37

Palisade Small Cap Core Equity 1.29

Renaissance Technologies Corp 1.29

Vanguard Institutional Extnd Mkt Idx Tr 1.10

Goldman Sachs Group Inc 1.09

Amvescap Plc. 1.06

Pacer Advisors, INC. 1.04

Trexquant Investment LP 1.03

Fidelity Small Cap Index 1.01

Schwab Fundamental U.S. Small CompanyETF 1.01

Invesco RAFI US 1500 Small-Mid ETF 1.01

Pacer US Small Cap Cash Cows 100 ETF 0.94

iShares Russell 2000 Value ETF 0.90

Vanguard Strategic Equity Inv 0.87

DFA US Targeted Value I 0.76

Dimensional US Targeted Value ETF 0.61

iShares Biotechnology ETF 0.58

Fidelity Extended Market Index 0.55

Vanguard Russell 2000 ETF 0.48

Schwab US Small-Cap ETF™ 0.48

Federated Hermes MDT SCC Institutional 0.46

Federated Hermes MDT Small Cap Core IS 0.46

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 1

Strong Sell: 0

Fundamentals

Market Cap 578.86 M

PB Ratio 0.9729

PE Ratio 8.2197

Enterprise Value 984.29 M

Total Assets 1389.70 M

Volume 888666

Company Financials

Annual Revenue FY23:1120900000 1120.9M, FY22:1120900000 1120.9M, FY21:1792700000 1792.7M, FY20:1555400000 1555.4M, FY19:1106000000 1106.0M

Annual Profit FY23:427200000 427.2M, FY22:427200000 427.2M, FY21:1035200000 1035.2M, FY20:1031400000 1031.4M, FY19:672500000 672.5M

Annual Net worth FY23:-223800000 -223.8M, FY22:-223800000 -223.8M, FY21:230900000 230.9M, FY20:305100000 305.1M, FY19:54500000 54.5M

Quarterly Revenue Q3/2025:231100000 231.1M, Q2/2025:140900000 140.9M, Q1/2025:222200000 222.2M, Q3/2024:293800000 293.8M, Q2/2024:254700000 254.7M

Quarterly Profit Q3/2025:139400000 139.4M, Q2/2025:60700000 60.7M, Q1/2025:119400000 119.4M, Q3/2024:164200000 164.2M, Q2/2024:-54500000 -54.5M

Quarterly Net worth Q3/2025:51200000 51.2M, Q2/2025:-12000000 -12.0M, Q1/2025:68000000 68.0M, Q3/2024:114800000 114.8M, Q2/2024:-283100000 -283.1M

Fund house & investment objective

Company Information Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Organisation Drug Manufacturers - Specialty & Generic

Employees 900

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow